Medicenna Therapeutics (MDNA) Corporate presentation summary

Pipeline overview and strategic focus

• Advancing a diversified pipeline with multiple near-term catalysts in oncology and immunology.

• Lead programs include Bizaxofusp (MDNA55), MDNA11, and MDNA113, each targeting significant unmet needs.

• Platform expansion into autoimmune and inflammatory diseases with preclinical candidates MDNA209 and MDNA413.

• Multiple clinical and preclinical milestones expected over the next 3–6 months.

• Cash runway extends into Q2 2027, supporting key development milestones.

Lead clinical programs and milestones

• Bizaxofusp doubled median overall survival in recurrent glioblastoma and is Phase 3-ready with regulatory designations.

• MDNA11, a next-gen IL-2 superkine, shows 30–40% response rates in checkpoint-resistant cancers; key data readouts in Q4 2026.

• MDNA113, a tumor-targeted anti-PD-1 x IL-2 bifunctional superkine, is completing IND-enabling studies with Phase 1 planned.

• Ongoing trials (ABILITY-1, NEO-CYT) are designed to inform registrational development for MDNA11.

• Upcoming catalysts include data presentations, IND submissions, and trial initiations across the pipeline.

Market opportunity and validation

• Bizaxofusp targets a $1.3B annual GBM market and $4B in other brain cancers.

• MDNA11 and MDNA113 address large markets in solid tumors and checkpoint-resistant cancers.

• Extensive independent validation of the IL-2 superkine platform by leading academic labs and publications.

• Recent industry deals highlight high strategic value for cytokine-based and bispecific immunotherapies.

• Platform offers long-term optionality beyond oncology, expanding into autoimmune and inflammatory indications.